Form PTQ-1449 (REV. 8-83)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. UCAL-253/02US

SERIAL NO. 09/281,717

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) JUL Q 1 1999

APPLICANT:

John D. Baxter, et al.

FILING DATE March 30, 1999 GROUP 1648 1631

TENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME ·	CLASS	SUBCLASS	FILING DATE
M).	P1	5,331,573	19 Jul 94	Balaji, et al	364	500	14 Dec 90
γ,	P2	5,500,807	19 Mar 96	Lavin, et al.	364	496	21 Feb 92

						TRANSLATI	ON
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
F1							
		,					

OTHER PUBLICATIONS (including Author, Title, Date, Pertinent Pages, Etc.)

M).	D1	ADAMS et al., "Cross-validated maximum likelihood enhances crystallographic simulated annealing refinement," Proc. Natl. Acad. Sci., Vol. 94, pp. 5018-5023, 1997
mo.	D2	APRILETTI et al., "Expression of the Rat α l Thyroid Hormone Receptor Ligand Binding Domain in Escheria coli and the Use of a Ligand-induced Comformation Change as a Method for its purification to Homogeneity," Protein Expr. Purif., Vol. 6, pp.363-370, 1995
ΔD	D3	BERRY et al., "Role of the two activating domains of the oestrogen receptor in the cell- type and promoter-context dependent agonistic activity of the anti-oestrogen 4-

hydroyamoxifen," EMBO J., Vol. 9, No. 9, pp. 2811-2818, 1990 BOURGUET et al., "Crystal Structure of the Ligand-binding domain of the Human Nuclear D4 Receptor RXR-α," Nature, Vol. 375, pp. 377-382, 1995

BRZOZOWSKI et al., "Molecular Basis of agonism and Antagonism in the oestrogen receptor," Nature, Vol. 389, pp. 753-758, 1997

CHANG et al., "A Thyroid Hormone Receptor Coactivator Negatively Regulated by the Retinoblastoma Protein," Proc. Natl. Acad. Sci. USA, Vol. 94, pp. 9040-9045, 1997

COHEN et al., "Molecular Modeling Software and Methods for Medicinal Chemistry," J. Med. Chem., Vol. 33, No. 3, pp. 883-894, 1990

COLLINGWOOD et al., "A Natural Transactivation Mutation in the Thyroid Hormone eta Receptor: Impaired Interaction with Putative Transcriptional Mediators," Proc. Natl. Acad. Sci. USA, Vol. 94, pp. 248-253, 1997

DESJARLAIS et al., "Using Shape Complementarily as an Initial Screen in Designing Ligands for a Receptor Binding Site of Known Three-Dimensional Structure," J. Med. Chem., Vol. 31, pp. 722-729, 1988

EXAMINER DATE CONSIDERED ענו/

MINER! Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO		INFORMATION DISCLOSURE STATEMENT OF THE UCAL-253/02US	SERIAL NO. 09/281,717				
		(Use several sheets if necessary) JUL 0 1 1999 APPLICANT: Ophn D. Baxter, et al. SILING DATE March 30, 1999	GROUP 1648 (63)				
<u></u>	D10	DING et al., "Nuclear Receptor-Binding Sites of Coactivators Glu Interacting Protein 1 (GRIP1) and Steroid Receptor Coactivator 1 (SRC with Different Binding Specificities," Molecular Endocrinology, Vol. 1	C-1): Multiple Motifs				
MD.	D11	ENG et al., "Probing the Structure and Function of the Estrogen Receptor Ligand Binding Domain by Analysis of Mutants with Altered Transactivation Characteristics," Molecular and Cellular Biology, Vol. 17, No. 8, pp. 4644-4653, 1997					
MD.	D12	FARMER, "Drug Design," Ariens, E.J., ed., Vol. 10, pp. 119-143, Academ	ic Press, NY, 1980				
	D13	FUREY et al., "'Phases' - A Program Package for the Processing and An. Data From Macromolecules," Am. Crust. Assoc. Mtg. Abstr., PA 33, Vol.					
MD.	D14	GLASS et al., "Nuclear Receptor Coactivators," Curr. Opin. Cell Bio., Vol. 9, pp. 222-232, 1997					
MD		GREENE et al., "Monoclonal Antibodies to Human Estrogen Receptor," Pr USA, Vol. 77, No. 9, pp. 5115-5119, 1980	roc. Natl. Acad. Sci.				
MD.	D16	GREENE et al., "Purification of T47D Human Progesterone Receptor Characterization with Monoclonal Antibodies," Molecular Endocrinology 714-726, 1988					
	D17	HEGY et al., "Carboxymethylation of the Human Estrogen Receptor Li Estradiol Complex: HPLC/ESMS Peptide Mapping Shows That Cysteine 447					

Indoacetic Acid," Steph'As, W. 6:367-373 (1996)

D18 HEERY et al., "A Signature Motif in Transcriptional Co-activators Mediates Binding to Nuclear Receptors," Nature, Vol. 387, pp. 733-736, 1997

D19 HENTTU et al., "AF-2 Activity and Recruitment of Steroid Receptor Coactivator 1 to the Estrogen Receptor Depend on a Lysine Residue Conserved in Nuclear Receptors," Molecular and Cellular Biology, Vol. 17, No. 4, pp. 1832-1839, 1997

D20 HONG et al., "GRIP1, a Novel Mouse Protein That Serves as a Transcriptional Coactivator in Yeast for the Hormone Binding Domains of Steroid Receptors," Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 4948-4952, 1996

D21 HONG et al., "GRIP1, a Transcriptional Coactivator for the AF-2 Transactivation Domain of Steroid, Thyroid, Retinoid, and Vitamin D Receptors," Molecular and Cell Biology, Vol. 17, No. 5, pp. 2735-2744, 1997

D22 HORWITZ et al., "Nuclear Receptor Coactivators and Corepressors," Molecular Endocrinology, Vol. 10, pp. 1167-1177, 1996

Expressed by Recombinant Vaccinia Virus, "Proc. Natl. Acad. Sci. USA, Vol. 88, pp. 8972-8976, 1991
 JURUTKA et al., "Mutations in the 1,25-Dihydroxyvitamin D3 Receptor Identifying C-Terminal Amino Acids Required for Transcriptional Activation That are Functionally Dissociated from Hormone Binding, Heterodimeric DNA Binding, and Interaction with Basal Transcription Factor IIB, in Vitro," J. Biol. Chem., Vol. 272, No.23, pp. 14592-14599, 1997

D25 KAKIZAWA et al., "Ligand-dependent Heterodimerization of Thyroid Hormone Receptor and Retinoid X Receptor," J. of Biol. Chem., Vol. 272, No. 38, pp. 23799-23804, 1997

JANKNETCHT et al., "Rapid and Efficient Purification of Native Histidine-tagged Protein

EXAMINER*

DATE CONSIDERED

AMINER Thitial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication to applicant.

Form PTO (REV. 8-		9 U.S. I MENT OF COMMERCE PATENT TRADEMARK OFFICE	ATTY. DOCKET NO. UCAL-253/02US	SERIAL NO. 09/281,717		
•	•	INFORMATION DISCLOSURE STATEMENT (Use several sheets if recessary)				
		JUL 0:1 1999 ©	APPLICANT: John D. Baxter, et al. FILING DATE	GROUP		
			March 30, 1999	1648 63		
-		PADEMARKO				
MD ←	D26	KAMEI et al., "A CBP Integrator Complex Inhibition by Nuclear Receptors," Cell, Vol		Activation and AP-1		
MD.	D27	KUIPER et al., "Comparison of the Ligar Distribution of Estrogen Receptors α and β , 1997		-		
ND.	D28	KUNTZ, "Structure-Based Strategies for Drug 1078-1082, 1992	Design and Discovery ," So	eience, Vol. 257, pp.		
MD.	D29	KUSSIE et al., "Structure of the MDM2 O Transactivation Domain," Science, Vol. 274,		53 Tumor Suppressor		
W.	D30	LANDEL et al., "Estrogen Receptor Accessor, DNA Bending," J. Steroid Biochem. Molec. Bio	· · · · · · · · · · · · · · · · · · ·			
M.	D31	LANDEL et al., "The Interaction of Human Estrogen Receptor with DNA Is Modulated by Receptor-Associated Proteins," Molecular Endocrinology, Vol. 8, pp. 1407-1419, 1994				
no.	D32	LANZENNEC et al., "Mechanistic Aspects of Estrogen Receptor Activation Probed with Constitutively Active Estrogen Receptors: Correlations with DNA and Coregulator Interactions and Receptor Conformational Changes," Molecular Endocrinology, Vol. 11, pp. 1375-1386, 1997				
No.	D33	LE DOUARIN et al., "A Possible Involvement TIF1 α and TIF1 β in the Epigenetic Control of Transcription by Nuclear Receptors," EMBO J., Vol. 15, No. 23, pp. 6701-6715, 1996				
MOO.	D34	LEE et al., "Thyroid Hormone Receptor Dimerization Function Maps to a Conserved Subregion of the Ligand Binding Domain," Mol. Endocrinol., Vol. 6, pp. 1867-1873, 1992				
W.	D35	LIN et al., "A Conformation Switch in Nuc Hormone Binding to Corepressor Release," Mo 1997	-			
m.	D36	MASUYAMA et al., "Evidence for Ligand-Dependent Intramolecular Folding of the AF-2 Domain in Vitamin D Receptor-Activated Transcription and Coactivator Interaction," Mol. Endocrinol., Vol. 11, pp.1507-1517, 1997				
m).	D37	MENG et al., "Automated Docking with Grid-Based Energy Evaluation," J. Computational Chem., Vol. 13, No. 4., pp. 505-524, 1992				
MD.	D38	MUELLER et al., "Complex Heterocyclic Structures - A Challenge for Computer-Assisted Molecular Modeling," Bull. Soc. Chim. Belg., Vol. 97, pp. 655-667, 1988				
Mo.	D39	MURSHUDOV et al., "Refinement of Macromolecular Structures by the Maximum-Likelihood Method," Acta Cryst:, Vol. D53, pp. 240-255, 1997				
	D40	NAVIA et al., "Use of Structural Information Vol. 2, pp. 202-210, 1992	on in Drug Design," Curr. (Opin. Struct. Biol.,		
Mo.	D41	NORMAN et al., "The Rat Growth Hormone Gene J. Biol. Chem., Vol. 264, No. 20, pp. 12063-		Response Elements,"		
Mv.	D42	Coactivator GRIP-1 Highlights the Role of Receptor Pharmacology," J. Biol. Chem., Vol.	273, No. 12, pp. 6679-6688	Determining Estrogen		
EXAMINER*	/	//	CONSIDERED			
[/] I A.	. /	///	_/			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) JUL 0 1 1939 APPLICANT: John D. Baxter, et al. FILING DATE March 30, 1999 JEAN 10 1999	Form PTO-144		ATTY. DOCKET NO.	SERIAL NO.
(Use several sheets if necessary) JUL 0 1 1999 APPLICANT: John D. Baxter, et al.	(REV. 8-83)	PATENT AND TRADEMAR DOES CE	0CAL-253/0205	09/281,717
JUL 0 1 1999 APPLICANT: John D. Baxter, et al.		INFORMATION DISCLOSURE STATEMENT		
John D. Baxter, et al.		(Use several sheets if necessary)	1	i
John D. Baxter, et al.		iii 8 1 1999 ♥	APPLICANT:	
FILING DATE GROUP March 30, 1999		\ _{\\}	John D. Baxter, et al.	
March 30, 1999 1548			FILING DATE	GROUP
TAAD COLOR TO THE		To want	March 30, 1999	1548 (63)
		MADEM		
		3 O'DONNELL et al., "Thyroid Hormone Recepto	w Mutations that Interfe	ro with Transariat

402	D43	O'DONNELL et al., "Thyroid Hormone Receptor Mutations that Interfere with Transcriptional Activation also Interfere with Receptor Interaction with a Nuclear Protein," Molecular Endocrinology, Vol. 5, pp. 94-99, 1991
	D44	ONATE et al., "Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily," Science, Vol. 270, pp. 1354-1357, 1995
MO.	D45	RADHAKRISHNAN et al., "Solution Structure of the KIX Domain of CBP Bound to the Transactivation Domain of CREB: A Model for Activator: Coactivator Interactions," Cell, Vol. 91, pp. 741-752, 1997
MD.	D46	RENAUD et al., "Crystal Structure of the RAR-γ Ligand-Binding Domain Bound to All-trans Retinoic Acid," Nature, Vol. 378, pp. 681-689, 1995
W.	D47	SAATCIOGLU et al., "Mutations in the Conserved C-Terminal Sequence in Thyroid Hormone Receptor Dissociate Hormone-Dependent Activation from Interference with AP1-Activity," Mol. Cell Biol., Vol. 17, No. 8, pp. 4687-4695, 1997
w.	D48	SADOVSKY et al., "Transcriptional Activators Differ in Their Responses to Overexpression of TATA-Box-Binding Protein," Molecular and Cellular Biology, Vol. 15, pp. 1554-1563, 1995
MW.	D49	SEIELSTAD et al., "Analysis of the Structural Core of the Human Estrogen Receptor Ligand Binding Domain by Selective Proteolysis/Mass Spectrometric Analysis," Biochemistry, Vol. 34, pp. 12605-12615, 1995
NO	D50	SEIELSTAD et al., "Molecular Characterization by Mass Spectrometry of the Human Estrogen Receptor Ligand-Binding Domain Expressed in Escherichia coli," Molecular Endocrinology, Vol. 9, pp. 647-658, 1995
m.	D51	SHIAU et al., "Activation of the Human Estrogen Receptor by Estrogenic and Antiestrogenic Compounds in Saccharomyces cereviviae: A Positive Selection System," Gene, Vol. 179, pp. 205-210, 1996
mo.	D52	SHIBATA et al., "Role of Co-activators and Co-repressors in the Mechanism of Steroid/Thyroid Receptor Action," Recent Prog. Horm. Res., Vol. 52, pp. 141-164, 1997
MD.	D53	SPENCER et al., "Steroid Receptor Coactivator-1 is a Histone Acetyltransferase," Nature, Vol. 389, pp. 194-198, 1997
M).	D54	TAGAMI et al., "Nuclear Receptor Corepressors Activate Rather than Suppress Basal Transcription of Genes That Are Negatively Regulated by Thyroid Hormone," Molecular and Cellular Biology, Vol. 17, No. 5, pp. 2642-2648, 1997
mo.	D55	TANENBAUM et al., "Crystallographic Comparison of the Estrogen and Progesterone Receptor's Ligand Binding Domains," Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 5998-6003, 1998
W.	D56	TORA et al., "The Cloned Human Oestrogen Receptor Contains a Mutation which Alters Its Hormone Binding Properties ," EMBO J., Vol. 8, No. 7, pp. 1981-1986, 1989
No.	D57	TORCHIA et al., "The Transcriptional Co-activator p/CIP Binds CBP and Mediates Nuclear-Receptor Function," Nature, Vol. 387, pp. 677-684, 1997
W.	D58	UESUGI et al., "Induced %. Helix in the VP 16 Activation Domain upon Binding to a Human TAF," Science, Vol. 277, pp. 1310-1313, 1996
M.	D59	VERLINDE et al., "Structure-Based Drug Design: Progress, Results and Challenges," Structure, Vol. 2, pp. 577-587, 1994
		

EXAMINER*

DATE CONSIDERED

AMINEN: Thitial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication to applicant.

						_	
Form PTO- (REV. 8-8		1	DE MENT OF C		ATTY. DOCKET NO. UCAL-253/02US		SERIAL NO. 09/281,717
(REV. 6-6	,,,	, FAISI	1 P	COFFICE	0CAB-2337 0203		05/281,717
		INFORMATION DISCLOS	• / •	. /			
		(Use several sheets	necessary)	<u>%</u>]	APPLICANT:		
			JUL 0. 1 199	g ω	John D. Baxter,	et al.	
			THE SALE OF THE		FILING DATE March 30, 1999		GROUP 1848 1631
			PADEMAR				
WD2	D60	WAGNER et al., "A 6 Vol. 378, pp. 690-69	Structural Role	for Hor	mone in the Thyro	oid Hormon	e Receptor," Nature
AW2	D61						ray: Potential Origin Endocrinol., Vol. 9
mo.	D62	WHITE et al., "Liga Conserved Tyrosine,"	-			-	or by Mutation of a
M. M. M.	D63	-	Contains Residu	es Vital	for Heterodimeriz	ation with	Domain of the Humar Retinoid X Receptor p. 1166-1179, 1995
m.	D64	WURTZ et al., "A Ca Nat. Struct. Biol.,				Domain of	Nuclear Receptors,
M.	D65		Mediated by Ir				n of Thyroid Hormone Chem., Vol. 272, No.
EXAMINER*	\bigwedge	Amy JOZ	-		DATE CONSIDERED	5/8/10	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include a copy of this form with the next communication to applicant.

407121 v1/PA 8Q4X01!.DOC